ANTHEM

TL;DR: Anthem's FY26 slowdown must prove to be temporary destocking: CRDMO orders should recover, Unit III should contribute and molecules should keep progressing toward commercialisation. Unit IV and new modalities add upside, but the high valuation leaves little tolerance for weak utilisation or delayed growth.

Read the full thesis → · Original research note →